Document Detail


Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking.
MedLine Citation:
PMID:  23039088     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Topiramate, presumably through antagonism of excitatory glutaminergic pathways and facilitation of inhibitory gamma-aminobutyric acid neurons in the cortico-mesolimbic system, might reduce cocaine's abuse liability. We tested whether topiramate (100 mg twice daily) would reduce the euphoria, subjective mood, craving and preference for cocaine over money induced by low and high doses (0.325 and 0.65 mg/kg i.v., respectively) of experimentally administered cocaine in 24 male and female, cocaine-dependent, non-treatment-seeking research volunteers in a university in-patient laboratory. We utilized a randomized, double-blind, placebo-controlled, within-subject, Latin-square cross-over design in which three experimental challenge doses of low-dose cocaine, high-dose cocaine and placebo were administered in counterbalanced order after 5 days of topiramate or matching placebo pre-treatments separated by a 1-week washout period (2006-2009). After placebo pre-treatments, cocaine produced dose-related increases in euphoria, stimulant effects, craving for more cocaine and monetary value of cocaine in a behavioral preference test of cocaine versus money choice. Topiramate pre-treatment reduced the cocaine-related craving and monetary value of high-dose cocaine while increasing the monetary value, euphoria and stimulant effects of low-dose cocaine. Validated and standardized human experimental methods evaluating the potential for topiramate to alter cocaine's abuse liability suggest that topiramate may reduce the reinforcing effects and craving induced by higher cocaine doses. Low-dose cocaine might appear to have some enhancement of its stimulant properties in the presence of topiramate's prominent sedative effects.
Authors:
Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Erik W Gunderson; Heather M Haughey; Xin-Qun Wang; Lei Liu
Related Documents :
23381958 - Drug-drug interaction study of act-178882, a new renin inhibitor, and diltiazem in heal...
23044768 - Andrographis paniculata extract (hmpl-004) for active ulcerative colitis.
23052408 - The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimu...
23075918 - Safety, tolerability, and pharmacokinetics of the hiv integrase inhibitor dolutegravir ...
7396148 - Midazolam: a water-soluble benzodiazepine. studies in volunteers.
17628788 - Subacute oral toxicity study of bisphenol f based on the draft protocol for the "enhanc...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-8
Journal Detail:
Title:  Addiction biology     Volume:  -     ISSN:  1369-1600     ISO Abbreviation:  Addict Biol     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9604935     Medline TA:  Addict Biol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 The Authors, Addiction Biology © 2012 Society for the Study of Addiction.
Affiliation:
Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dendritic spine density is altered in a mouse model of Cockayne syndrome.
Next Document:  Spatial gene expression quantification: a tool for analysis of in situ hybridizations in sea anemone...